CRDF

Cardiff Oncology, Inc.

CRDF · CIK 1213037 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$1M
20182025
Net Income−$46M
20182025
Operating CF−$38M
20182025
Free Cash Flow−$38M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue——————$0.0B$0.0B
Gross Profit————————
R&D Expense———$0.0B$0.0B$0.0B——
SG&A Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Operating Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-0.69$-0.95$-0.93$-0.89$-0.73——$-8.26
EPS (Diluted)$-0.69$-0.95$-0.93$-0.89$-0.73——$-8.26

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B
Current Assets$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B
Cash & Equivalents$0.0B$0.1B$0.0B$0.0B$0.0B$0.1B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B—
Investing Cash Flow$0.0B$0.0B$0.0B$0.0B$-0.1B$-0.0B$-0.0B—
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.1B$0.0B$0.0B$0.0B$0.1B$0.0B—
← Companies